SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs SL 401 (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions
- Sponsors Stemline Therapeutics
- 31 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2018.
- 31 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 06 Dec 2016 Results evaluating safety presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.